Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 112 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Real-World Clinical Outcomes of Trilaciclib for the Prevention of Myelosuppression in Patients with Esophageal Cancer Undergoing Chemotherapy
Hui Chen, Jingze Yan, Zeyuan Liu,Xiaolin Ge,Xinchen Sun, Xiaojie Xia
Current oncology (Toronto, Ont)no. 4 (2025)
Cited0Views0WOSBibtex
0
0
Definitive Chemoradiotherapy Combined with Anti-Pd-1 Immunotherapy for Inoperable Esophageal Squamous Cell Carcinoma: a Multicenter Real-World Study
Xiongtao Yang,Xiaomin Wang,Qin Xiao,Xiaolin Ge, Nuo Yu,Jiao Li, Guojie Feng, Ziyu Zheng, Yingying Jiang, Lin Lu, Xiaojie Xia,Lei Deng,Tao Zhang, Wenqing Wang,Wenyang Liu,Jianyang Wang,Zefen Xiao,Zongmei Zhou,Nan Bi,Hui Wang,Cheng Chen,Xin Wang
Cancer biology & therapyno. 1 (2025): 2504726-2504726
Cited0Views0WOSBibtex
0
0
Tislelizumab Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Locally Advanced Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Parallel-Controlled, Phase II Clinical Trial
Wencheng Zhang, Ke Zhang, Qifeng Wang, Jianzhong Cao, Chengcheng Fan, Wenbin Shen,Qin Xiao,Xiaolin Ge, Xiao Liu, Tian Zhang,Xi Chen, Jie Dong, Zewei Li, Zhunhao Zheng,Cihui Yan,Qingsong Pang,Ping Wang
Journal of Clinical Oncologyno. 16_suppl (2024): TPS4183-TPS4183
Cited0Views0Bibtex
0
0
Load More
Author Statistics

#Papers: 112

#Citation: 797

H-Index: 15

G-Index: 22

Sociability: 6

Diversity: 4

Activity: 14

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn